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Abstract
Introduction: Clinical resistance is a major factor limiting benefits to endocrine therapy. Causes of resistance may
be diverse and the mechanism of resistance in individual breast cancers is usually unknown. The present study
illustrates how changes in the expression of proliferation and oestrogen-regulated genes occurring during
neoadjuvant treatment with the aromatase inhibitor, letrozole, may define distinctive tumour subgroups and
suggest different mechanisms of resistance in clinically endocrine resistant breast cancers.
Methods: Postmenopausal women with large primary oestrogen-receptor (ER)-rich breast cancers were treated
neoadjuvantly with letrozole (2.5 mg daily) for three months. Clinical response was determined by ultrasound
changes in tumour volume. Tumour ribonucleic acid (RNA) from biopsies taken before, after 14 days and after
three months of treatment was hybridized on Affymetrix U133A chips. Changes in expression of KIAA0101, TFF3,
SERPINA3, IRS-1 and TFF1 were taken as markers of oestrogen regulation and those in CDC2, CKS-2, Cyclin B1,
Thymidine Synthetase and PCNA as markers of proliferation.
Results: Fifteen tumours with < 50% volume reduction over three months of treatment were classified as being
clinically non-responsive. Gene expression changes after 14 days of treatment with letrozole revealed different
patterns of change in oestrogen regulated and proliferation genes in individual resistant tumours. Tumours could
be separated into three different subgroups as follows: i) nine cases in which both proliferation and oestrogen
signalling signatures were generally reduced on treatment (ii) four cases in which both signatures were generally
unaffected or increased with treatment and (iii) two cases in which expression of the majority of oestrogen-
regulated genes decreased whereas proliferation genes remained unchanged or increased. In 14 out of 15
tumours, RNA profiles were also available after three months of treatment. Patterns of change observed after 14
days were maintained or accentuated at three months in nine tumours but changes in patterns were apparent in
the remaining five cancers.
Conclusions: Different dynamic patterns of expression of oestrogen-regulated and proliferation genes were
observed in tumours clinically resistant to neoadjuvant letrozole, thus illustrating heterogeneity of resistance and
discriminating molecular sub-classes of resistant tumours. Molecular phenotyping might help to direct
circumventing therapy suggesting the targeting of specific pathways in different tumour subtypes.
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Endocrine therapy is a major treatment modality for
breast cancer but its utility is limited by both primary
and acquired resistance [1-3]. Current selection for the
treatment is based on presence of oestrogen receptors
(ER) in the tumour [4-7]. The growth of many ER-posi-
tive tumours slows in response to oestrogen deprivation;
however, some tumours fail to respond, despite the pos-
session of oestrogen receptors [8,9]. Moreover, the
majority of patients, who initially respond to treatment,
develop resistance later. At present, there are no rational
targeted therapies to overcome endocrine resistance and
no clinical markers to predict resistance in ER-positive
breast tumours. Patient management would benefit from
accurate identification of (i) tumours most likely to
r e s p o n dt ot r e a t m e n ta n d( i i )t h em e c h a n i s m so fr e s i s -
tance in individual non-responsive cancers. In order to
address these issues, a neoadjuvant therapy with letro-
zole, a specific aromatase inhibitor which reduces endo-
genously synthesised oestrogen [10], has been employed
[11]. The study reports molecular profiles in sequential
biopsies taken from breast tumours during the course of
treatment. This design allows assessment of dynamic
changes in gene expressions in individual tumours. Pre-
sent analysis concentrates on the heterogeneity of gene
expression changes within the resistant tumours focuss-
ing on genes associated with proliferation and oestrogen
signalling.
Materials and methods
Patients
All patients were postmenopausal women presenting to
the Edinburgh Breast Unit with large primary ER-rich
( A l l r e ds c o r e>5 )b r e a s tc a n c e r sb u tw i t h o u te v i d e n c e
of distant metastatic disease. Informed consent was
obtained for inclusion in the study which had been
approved by the local ethics committee (LREC 2001/8/
80 and LREC 2001/8/81). Neoadjuvant treatment was
with letrozole (Femara, [Novartis Pharma AG, Basel,
Switzerland] 2.5 mg daily) for three months [11]. Clini-
cal response was based on changes in tumour volumes
over three months determined from ultrasound mea-
surements (performed by a single operator). Tumours
with < 50% reduction in volume were classified as non-
responders. Demographics of patients with clinically
resistant tumours are summarized in Table 1.
Tumour processing and RNA extraction
Multiple core biopsies were taken with a 14 gauge nee-
dle before and after 10 to 14 days of treatment. In most
of the cases the tumour was also available after three
months of treatment. Tissue samples were immediately
snap-frozen and stored in liquid nitrogen. Frozen
sections were taken to confirm the presence of cancer-
ous tissue. Biopsies in which the malignant component
comprised at least 20% of the section area were pul-
verised using U2 micro-dismembranator U (Braun Bio-
tech, Melsungen, Germany). Total RNA was extracted
f r o mt h ef r o z e nt i s s u ep o w der using TRI-reagent
(Sigma, Poole, Dorset, UK). Before microarray analysis,
the extracted RNA was further purified on RNeasy mini
columns (Qiagen, Crawley, West Sussex, UK).
Microarray analysis
R N A( 5 0 0n g )w a ss u b j e c tt ot w or o u n d so fa m p l i f i c a -
tion [12]. The resulting cRNA was converted to double-
stranded DNA and biotinylated cRNA was generated
using the Enzo kit (Affymetrix, Santa Clara, California,
USA). Biotinylated cRNA was fragmented and hybri-
dized on Affymetrix (Santa Clara, CA, USA) HG_U133A
chips as described in the standard protocol outlined in
the Gene Chip Expression Analysis Technical Manual
(Affymetrix). Microarrays were scanned with an Affyme-
trix 3000 laser scanner. Rawe x p r e s s i o nv a l u e sf r o m
Affymetrix’ CEL files were normalised using Robust
Multichip Average methodology [13-16]. The method
adjusts for background noise on chips and summarizes
data into expression values, one number per gene per
sample. Primary microarray data are available from the
Gene Expression Omnibus [17] with series numbers
[GEO:GSE5462] and [GEO:GSE20181]).
Table 1 Patient and tumour characteristics
Age at diagnosis Years
Median 79
Range 63 to 86
Tumour size n (%)
T2 11 (73)
T3 1 (7)
T4 3 (20)
Lymph node status n (%)
+ve 2 (13)
-ve 13 (87)
Histological grade n (%)
1 1 (7)
2 9 (60)
3 4 (26)
Unknown 1 (7)
Progesterone receptor n (%)
+ve 11 (73)
-ve 4 (27)
HER2 n (%)
+ve 2 (13)
-ve 13 (87)
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proliferation
Marker genes classically associated with oestrogen regu-
lation were KIAA0101 (202503_s_at), TFF3 (204623_at),
SERPINA3 (202376_at), IRS1 (204686_at), TFF1
(205009_at) and those associated with cell proliferation
were CDC2 (203213_at), Cyclin B1 (214710_s_at), CKS2
(204170_s_at), TYMS (202589_at), PCNA (201202_at).
They were chosen because of previous literature indicat-
ing these associations [18-26] and having been demon-
strated to be detectably expressed by this series of breast
cancers [27]. They included oestrogen regulated genes
resulting from interactions at both ERE and AP-1 sites.
Single probes were present on the chip for all genes apart
from KIAA0101, CDC2 and TYMS for which the most
specific probe was selected. All expression calls were
positive before treatment and > 90% overall.
Real-time quantitative PCR
Microarray measurements forf o u ro ft h es t u d i e dg e n e s
were verified by real time PCR. These included two oes-
trogen regulated (SERPINA3 and TFF1)a n dt w oc e l l
cycle associated (CCNB1 and CDC2) genes. In brief,
mRNA was converted to cDNA using oligo-dT primers
and SS-III reverse transcriptase (Invitrogen), according
to the manufacturer’s instructions. Real time PCR was
run using Quantitect SYBR-green PCR mix (Qiagen) on
Opticon Monitor 2 machine (Biorad MJR, Bio-Rad
Laboratories Ltd, Hemel Hempstead, Hertfordshire, UK)
as described [28]. Expression was normalised by geo-
metric mean of three stably expressed reference genes
[29,30]. Primer sequences designed using Primer3 soft-
ware (Enzo Life Sciences, Exeter, UK) [31] are shown in
Table S1 in Additional file 1.
Results
Clinical response/resistance
A total of 58 tumours were analysed for genomic
changes [27]. Of these, clinical response was not assessa-
ble in six because of inconsistencies in assessments by
calipers, ultrasound, mammography and microscopy.
The remaining 52 tumours were classified as 37 (71%)
responders and 15 (29%) non-responders [11]. The latter
tumours represent the cases analysed in the present
paper. Histologically, all were of no special type. Other
demographics are listed in Table 1.
Oestrogen receptor scores
Eleven tumours had an Allred score of 8: the remaining
scored 7 before therapy. Treatment produced no or only
minor effects (+/- 1) on staining apart from a single
tumour in which scores fell successively from 8 to 7 to
5 with increased time of therapy. These results are
similar to those published previously for the extended
group including responsive tumours [32].
Changes in gene expression associated with therapy in
clinical non-responders
Changes in studied markers after 10 to 14 days of treat-
ment are illustrated in Figures 1 and 2. Although the
general trend for oestrogen regulated genes was a
decrease in expression (Figure 1), group differences with
treatment were not statistically significant apart from
SERPINA3 (P = 0.045 by paired Wilcoxon rank test).
Neither were there consistent changes (Figure 2) nor
significant differences with treatment in individual genes
associated with proliferation. Patterns of gene changes
occurring after 10 to 14 days of treatment are illustrated
in a heat map (Figure 3). This highlighted differences
between individual resistant tumours, which could be
sub-grouped according to whether (i) both markers of
oestrogen regulation and proliferation were decreased
(nine cases - Group 1), (ii) all markers were only mar-
ginally changed (four cases - Group 2) and (iii) markers
for oestrogen regulation were decreased whereas those
for proliferation were unchanged/increased (two cases -
Group 3).
Changes in molecular phenotype at three months
Tumours were also availablea f t e rt h r e em o n t h so f
treatment. Microarray analysis was successfully per-
formed on 14 of these specimens. Patterns of changes
between (i) Day 0 and 10 to 14 days and (ii) Day 0
and three months of treatment are illustrated in a heat
map in Figure 4. Of the nine cases in which 10-to-14-
day treatment was associated with reduced expression
of both oestrogen regulated and proliferation markers
(Group 1), microarray results at three months were
available for eight cases. In five of them expression of
the markers continued to be reduced in comparison
with pre-treatment levels and often were further sup-
pressed in relation to the 10-to-14-days; in two cases
(#30 and #36) both oestrogen-regulated and prolifera-
tion marker mRNAs returnedt o w a r dp r e - t r e a t m e n t
values; and in the remaining tumour (#33) oestrogen
regulated markers were further suppressed at three
months whereas proliferation markers returned toward
pre-treatment levels. Of the four cases from Group 2
(marginal changes in the studied genes at 14 days),
two tumours still had only marginal changes at three
months, whereas two cases (#42 and #53) displayed
clear reduction in expression of the genes. Finally both
tumours with differential changes in expression of oes-
trogen regulated and proliferation genes (group 3)
maintained this phenotype at three months as well as
at 14 days.
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The expression of SERPINA, TFF1, CCNB1 and CDC2 were
also measured by qRT-PCR in 42 of the tumour samples
assayed by microarray. Results for the correlation coeffi-
cients and corresponding significance values are summar-
ized in Table S2 in Additional file 2. Highly significant
positive correlations were detected between the two meth-
odologies for each gene (including responding cases from
the total database greatly increases the number of sample
comparisons and the P-values are < 10
-15 for each gene).
Discussion
Oestrogen deprivation is a major therapeutic option
used to treat hormone sensitive breast cancer [33].
Blockade of oestrogen synthesis using aromatase inhibi-
tors occupies a central role in the management of
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Figure 1 Levels of oestrogen-regulated genes before (pre) and after treatment with Letrozole (10 to 14 days).
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Figure 2 Levels of proliferation-associated genes before (pre) and after treatment with Letrozole (10 to 14 days).
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tive tumours. Agents such as letrozole, anastrozole and
exemestane have great potency and specificity [10,34-36]
and also can be used to examine the molecular effects
of oestrogen deprivation in breast cancers in vivo
[27,37,38]. However, not all ER-positive tumours
respond to aromatase inhibitors [1,33] and there is,
therefore, a need for molecular markers which predict
response to treatment and elucidate molecular mechan-
isms associated with different mechanisms of resistance.
An important element of the latter is to determine the
effects of treatment on expression of oestrogen regu-
lated genes and proliferative pathways in tumours resis-
tant to treatment. Given the potential diversity of
resistance mechanisms, there are major advantages in
using a neoadjuvant protocol in which effects of treat-
ment may be monitored and correlated with clinical
response in individual tumours. An additional strength
of neoadjuvant therapy is that the accessibility of the
primary breast cancer means that clinical response may
be accurately assessed by sequential measurement of
tumour volume and the cancer may be serially biopsied
to monitor changes in gene expression. These
characteristics mean that meaningful analyses can be
performed by studying relatively small numbers of
tumours.
The present paper is based on expression changes in a
gene subset derived from a genome-wide microarray
analysis of biopsies of 52 breast cancers including the
f o c u ss u b g r o u po f1 5t u m o u r s ,c l i n i c a l l yr e s i s t a n tt o
neoadjuvant treatment with letrozole. Expression of
SERPINA3, TFF1, CCNB1 and CDC2 was also analysed
by quantitative RT-PCR. For all these validated genes,
PCR and microarray measurements showed highly sig-
nificant positive correlations on both the total dataset
and the subset of the resistant cases. However, despite
the highly significant correlations there was a small
number of gross outliers. (This may account for the
paradoxical changes seen in the TFF3 found in tumour
#59, which were increased in expression at both 14 days
and three months.) To account for occasional outlying
results, we used five genes for each of studied pathways.
Thus, expression of KIAA0101, insulin receptor substrate
1, SERPINA3 and trefoil factors 1 and 3 is either induced
by oestrogen or reduced by oestrogen deprivation/anti-
oestrogens in experimental systems [19-22,39-41] and
ER-associated
genes
Proliferation
genes
Group 1 Group 3 Group 2
-2.5 0 +2.5
Figure 3 Heterogeneity of endocrine-resistant tumours. Heatmap illustrates changes after 10 to 14 days of treatment with Letrozole: Green
represents a decrease in mRNA expression, red represents an increase in mRNA expression, brightness of colour corresponds to the degree of
changes. Scale in log to the base 2.
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It is worth commenting that although the expression of
these genes is down-regulated with letrozole treatment,
similar differential changes were observed in genes such
as COLEC12 and HTRA1 which were up-regulated by
letrozole treatment (data not shown). CDC 2, Cyclin B1,
CKS2, TYMS and PCNA are intimately involved in pro-
liferative processes and are often down-regulated by oes-
trogen deprivation in oestrogen-responsive systems in
vitro [19,26,42]. As a result of measuring these markers
in sequential biopsies during treatment, it was possible
to show variation in molecular responses between indi-
vidual endocrine-resistant cases. Thus, by using differ-
ences in patterns observed after short-time treatment
(10 to 14 days) tumours could be allocated to sub-
groups, namely: (i) cases in which both markers of oes-
trogen regulation and proliferation were generally
decreased, (ii) cancers in which expression of most of
the examined genes was only marginally affected and
(iii) those in which changes in oestrogen-regulated and
proliferation genes were disconnected: markers for oes-
trogen regulation were decreased whereas those for pro-
liferation were unaffected/increased by treatment. This
would be in keeping with the diversity of mechanisms
by which it has been proposed that tumours may
become resistant to aromatase inhibitors [8,43] and
other endocrine therapies [19,44-46]. In the majority of
cases analysed in this study, clinical resistance was para-
doxically associated with r e d u c t i o ni ne x p r e s s i o no f
most oestrogen-regulated and proliferation genes (Figure
3: Group 1). Additionally, all seven tumours in this
group which were PgR-positive displayed a reduction in
staining intensity and score with treatment. All had a
reduction in Ki67 score (apart from a case with low
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Figure 4 Sequential changes in genes expression in individual tumours. The left bar represents changes between pre-treatment and 14
days (14 D) and the right bar represents changes between pre-treatment and three months (3 M).
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15.6 before treatment, 6.0 after 14 days and 5.6 after
three months of treatment. Thus, whilst these tumours
are categorized as clinical non-responders, they do react
to oestrogen deprivation at molecular and proliferative
levels.
The major issue to clarify is why molecular and pro-
liferative responses associated with oestrogen depriva-
tion by letrozole do not translate into clinical
responses. There are several potential reasons. First, it
may reflect limitations and inaccuracy of clinical mea-
surements. Current clinical criteria for response assess-
ment are often based on arbitrary empirical thresholds
and it may be that clinical measurements do not
reflect biological responses. Thus, in the present study
tumours have been categorized as clinically resistant
on the basis of less than 50% reduction in tumour
volume. However, nine of these clinically resistant
tumours still had > 25% reduction. These tumours
might have become clinical responders with extended
treatment (we have shown that volume reduction con-
tinues beyond three months with letrozole [47,48] and
other forms of endocrine therapy [49]). In such cases
the molecular profiling may complement clinical mea-
surements in response assessment. Another reason for
the disparity between molecular and clinical responses
is that the molecular phenotypes were transient, and
compensatory changes occurred in gene expression.
However, evidence for these were observed in only the
minority of tumours, and in the remainder the
decrease in gene expression was even greater at three
months than at 10 to 14 days. Finally, it should be
emphasized that treatment did not decrease gene
expression to zero and, after therapy, expression is still
measurable. Hence, it could be argued that the relative
reductions in proliferation are not sufficient to produce
a clinical response in the absence of other changes
such as an increase in cell death.
Cases in which gene expression was only marginally
affected appear to have the classical phenotype of oes-
trogen insensitivity (Figure 3: Group 2). However,
before labelling such tumours as oestrogen resistant,i t
needs to be confirmed that the patients were drug
compliant and that 10 to 14 days of treatment reduced
both circulating and intratumoural levels of oestrogen.
Interestingly, in two of these tumours, gene expression
was reduced at three months possibly indicating that
endocrine and clinical response might require a more
prolonged treatment. Parallel changes were seen in
Ki67 staining with a median score of 6.2 before treat-
ment, 5.4 after 14 days and 3.4 after three months’
treatment.
A differential phenotype in which expression of oes-
trogen-regulated genes was mostly reduced but that for
proliferation genes was generally increased was observed
in two tumours (Group 3). Interestingly, this was also
evident in the protein staining for progesterone receptor
(which was positive and decreased with treatment in
both tumours) and Ki67 (mean value before treatment
12.3 and 16.6 after 14 days treatment). The disconnec-
tion between expression of oestrogen signalling and pro-
liferation genes was not transient and was observed at
both 10 to 14 days and three months (although Ki67
staining was markedly decreased at three months in
both cases - mean score 3.6). The most obvious expla-
nation for this phenomenon is that whilst oestrogen
regulated genes are still controlled by oestrogen, prolif-
eration (and growth) is determined by other non-oestro-
genic pathways. Of note, these two tumours did not
carry HER2 amplification.
The above discussion reflects the complexity and het-
erogeneity of molecular changes occurring within a rela-
tively small series of clinically resistant tumours
following neoadjuvant treatment with the aromatase
inhibitor, letrozole. This would be compatible with the
diversity of molecular mechanisms leading to resistance.
It should be noted that this heterogeneity is indepen-
dent of ER score which was not, or marginally, changed
with treatment. Furthermore, since changes in genes
classically associated with oestrogen regulation are fre-
quently seen with treatment, primary clinical resistance
to letrozole should not be equated to hormone-insensi-
tivity at molecular level. Indeed it could be that in some
cases specific non-canonical molecular changes pro-
duced by treatment may be the cause of clinical resis-
tance. The challenge remains to explain why marked
reductions in proliferation do not always translate into
clinical response (and, as a consequence, do not provide
robust markers for response prediction in individual
patients). A greater understanding of the molecular pro-
cesses involved and a systematic study of factors such
as, i) whether circulating and intratumoural oestrogen
are reduced, ii) the patency of oestrogen signalling path-
ways, iii) the degree to which proliferation is sup-
pressed, and iv) the involvement of other pathways
signalling for growth and cell survival in individual
tumours appear to be important and necessary steps by
which to optimise treatment with aromatase inhibitors
such as letrozole.
Conclusions
These data demonstrate that dynamic assessment of
oestrogen signalling and proliferation during treatment
with letrozole can identify distinctive molecular
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endocrine therapy.
Additional material
Additional file 1: Supplementary table S1. PCR primers’ sequences.
Additional file 2: Supplementary table S2. Correlations between PCR
and Microarray measurements.
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